From drug registration to post-market pharmacovigilance — plain-English guidance on the full regulatory lifecycle for pharmaceutical, biotech and medical-device companies doing business in China, and the lawyers who handle it.
Pharmaceuticals is one of the most heavily regulated, highest-risk sectors in China. A single misstep can carry administrative penalties, criminal liability and massive civil claims — often all at once.
Specialised rules and normative documents governing the pharma sector at national level.
Core compliance areas spanning a drug's entire life from R&D to market withdrawal.
Anti-corruption and counterfeiting cases routinely cross from fines into criminal prosecution.
Import, MRCT, HGR and data-transfer rules tie China operations to global compliance (FCPA, UKBA).
Nine practice areas covering a drug's full lifecycle in China.
Strategy under the MAH system; IND/NDA/ANDA support; accelerated pathways — priority review, breakthrough therapy and conditional approval.
Manufacturing and distribution quality systems, unannounced-inspection response, traceability and cold-chain compliance.
Ethics review, informed consent, human genetic resources (HGR) approvals and data-integrity compliance across the trial lifecycle.
HCP-interaction compliance, compliance-program building, internal investigations and defence — under both FCPA and China law.
Patent linkage, patent challenges, first-generic exclusivity, data exclusivity and trade-secret protection.
NRDL negotiation and bidding entry, volume-based procurement (VBP) tenders, pricing antitrust and insurance-fund supervision.
GVP system building, adverse-event reporting, post-authorization safety studies, recalls and product-liability disputes.
License-in / license-out due diligence, multi-regional clinical trials (MRCT), cross-border data flows and import registration.
Ad content review, Rx vs OTC restrictions, online drug-information licences and online drug sales compliance.
Who holds the licence, who bears the liability — and how MAH transfers work.
Rep registration and compliant speaker-fee and meeting rules after the 2023 crackdown.
The P1–P4 declarations, the 45-day window and the 12-month first-generic exclusivity.
HGR approvals, filing and "foreign party" rules — one of the most sensitive areas.
Bid compliance, supply-security contracts and the penalties for failure to supply.
PIPL, DSL and HGR overlap across clinical, real-world and pharmacovigilance data.
Pharma compliance risk spans administrative, civil and criminal liability. These are the scenarios we see most often.
| Scenario | Conduct | Risk | Legal consequence |
|---|---|---|---|
| Kickbacks / rebates | Paying doctors rebates or kickbacks tied to prescribing volume, or funnelling benefits through sham services. | Criminal | Bribery of non-state functionaries (PRC Criminal Law Art. 164) and acceptance of bribes (Art. 163); both the company and individuals can face criminal liability of up to 10+ years. |
| Clinical data falsification | Fabricating or altering trial data, selective reporting of results, or concealing adverse events. | Criminal Admin | Refusal or revocation of drug registration (administrative); the crime of providing false supporting documents (Art. 229); a 3-year bar on further trial applications. |
| Manufacturing counterfeit / substandard drugs | Producing products that fail drug standards, passing non-drugs off as drugs, or adding undeclared active ingredients. | Criminal | The crimes of producing or selling counterfeit drugs (Art. 141) and substandard drugs (Art. 142), with fines of 2×+ of sales value; the counterfeit-drug offence carries a possible death penalty. |
| Failure to report serious adverse reactions | Not reporting serious adverse reactions to the drug authority within the statutory time limit. | Admin | Fines of CNY 50,000–500,000; in serious cases, suspension of production or revocation of the approval document and manufacturing licence. |
| Non-compliant advertising | Advertising prescription drugs to the public, or publishing false or misleading drug ads without review. | Admin Civil | Heavy administrative fines (up to 5× the advertising fee); civil liability — consumers may claim treble damages under the Consumer Protection Law. |
| Unauthorised HGR export | Providing Chinese genetic data or biological samples to foreign parties without approval or filing. | Admin Criminal | Ministry of Science & Technology sanctions — suspension of projects or revocation of approvals; serious cases may be referred for criminal prosecution (Art. 334-1). |
| Post-VBP supply default | Failing to supply after winning a tender without good cause, selective supply, or lowering quality standards. | Admin Civil | Placement on the "violation list" and loss of VBP eligibility for all products for a set period; liability to hospitals for breach of the supply contract. |
A full compliance scan of your operations, identifying key risks and delivering a written assessment.
Tailored compliance programs and executable SOPs built around both regulation and commercial goals.
Layered compliance training for management and key roles so the program becomes part of daily operations.
Ongoing counsel that tracks regulatory change and steps in first when a crisis hits.